Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Egetis Therapeutics AB's Enterprise Value is kr3,094.36 Mil.
Egetis Therapeutics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr-301.20 Mil. Therefore, Egetis Therapeutics AB's EV-to-FCF for today is -10.27.
The historical rank and industry rank for Egetis Therapeutics AB's EV-to-FCF or its related term are showing as below:
OSTO:EGTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.87 Med: -5.73 Max: 0.46
Current: -12.22
During the past 13 years, the highest EV-to-FCF of Egetis Therapeutics AB was 0.46. The lowest was -20.87. And the median was -5.73.
OSTO:EGTX's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 16.05
vs OSTO:EGTX: -12.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egetis Therapeutics AB (OSTO:EGTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egetis Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Egetis Therapeutics AB's share price for today is kr7.33.
Egetis Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EGTX vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's EV-to-FCF falls into.
Egetis Therapeutics AB's current Enterprise Value is kr3,094.36 Mil.
Egetis Therapeutics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-301.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (OSTO:EGTX) has a EV-to-FCF of -10.27 as of Aug. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 321 companies in the Biotechnology industry.
Is Egetis Therapeutics AB's EV-to-FCF too high?
Egetis Therapeutics AB's current EV-to-FCF is -10.27. Based on the distribution chart, Egetis Therapeutics AB ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 321 companies for EV-to-FCF. This places Egetis Therapeutics AB in the lower half of its industry. The industry median EV-to-FCF is 16.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.05, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current EV-to-FCF is -10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (OSTO:EGTX) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.65, compared to a current price of kr7.33 — trading 29.7% above its estimated fair value. The current EV-to-FCF is -10.27. Egetis Therapeutics AB's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Egetis Therapeutics AB (OSTO:EGTX), the current EV-to-FCF is -10.27 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (OSTO:EGTX) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of kr7.33 is trading 29.7% above its estimated GF Value™ of kr5.65.
GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.
Key valuation signals for OSTO:EGTX:
EV-to-FCF: -10.27
GF Value™: kr5.65 vs. price of kr7.33 (29.7% above fair value)
No single metric tells the full story. See the OSTO:EGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
65GF Score
Get the complete analysis for OSTO:EGTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EGTX has been successfully added to your 
